Grace Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

GRCE$1.87+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	September 30, 2025	March 31, 2025
(Expressed in thousands except share data)	$	$
Assets
Current assets:
Cash and cash equivalents	16,862	22,133
Receivables	20	126
Prepaid expenses	416	453
Total current assets	17,298	22,712
Equipment, net	12	15
Intangible assets	41,128	41,128
Goodwill	8,138	8,138
Total assets	66,576	71,993
Liabilities and Stockholders’ equity
Current liabilities:
Trade and other payables	1,245	1,930
Total current liabilities	1,245	1,930
Derivative warrant liabilities	201	1,141
Deferred tax liability	2,312	2,312
Total liabilities	3,758	5,383
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 10,000,000 authorized; none issued and outstanding as of September 30, 2025 and March 31, 2025	—	—
Common stock, $0.0001 par value per share; 100,000,000 authorized; 14,128,562 and 13,718,106 shares issued and outstanding as of September 30, 2025 and March 31, 2025, respectively	1	1
Additional paid-in capital	293,842	293,334
Accumulated other comprehensive loss	(6,038)	(6,038)
Accumulated deficit	(224,987)	(220,687)
Total stockholders' equity	62,818	66,610
Total liabilities and stockholders’ equity	66,576	71,993

Condensed Consolidated

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.